Updating results

1346 results

Sort: Relevance | Date

Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Proposed [GID-QS10106] Expected publication date: TBC

Quality standard Proposed

Gout

Proposed [GID-QS10100] Expected publication date: TBC

Quality standard Proposed

Blood transfusion in neonatology

Proposed [GID-QS10098] Expected publication date: TBC

Quality standard Proposed

Readmission to ICU within 48hrs

Proposed [GID-QS10105] Expected publication date: TBC

Quality standard Proposed

Nutrition in hospital

Proposed [GID-QS10104] Expected publication date: TBC

Quality standard Proposed

Managing symptoms with an uncertain cause

Proposed [GID-QS10103] Expected publication date: TBC

Quality standard Proposed

Shared decision-making: practical guidance for health and social care professionals

Proposed [GID-QS10097] Expected publication date: TBC

Quality standard Proposed

Infant, children and young people's experience of health care

Proposed [GID-QS10102] Expected publication date: TBC

Quality standard Proposed

Sleep disordered breathing

Proposed [GID-QS10096] Expected publication date: TBC

Quality standard Proposed

Heart valve disease in adults

Proposed [GID-QS10101] Expected publication date: TBC

Quality standard Proposed

Perioperative care

Proposed [GID-QS10094] Expected publication date: TBC

Quality standard Proposed

Primary hyperparathyroidism

Proposed [GID-QS10089] Expected publication date: TBC

Quality standard Proposed

Thyroid disease

Proposed [GID-QS10088] Expected publication date: TBC

Quality standard Proposed

Parenteral nutrition in neonates

Proposed [GID-QS10087] Expected publication date: TBC

Quality standard Proposed

Diverticular disease

Proposed [GID-QS10086] Expected publication date: TBC

Quality standard Proposed

Pancreatitis (including acute pancreatitis)

Proposed [GID-QS10085] Expected publication date: TBC

Quality standard Proposed

Pain management (young people and adults)

Proposed [GID-QS10093] Expected publication date: TBC

Quality standard Proposed

Primary and secondary brain cancers

Proposed [GID-QS10092] Expected publication date: TBC

Quality standard Proposed

Tinnitus

Proposed [GID-QS10091] Expected publication date: TBC

Quality standard Proposed

Housing: planning to improve health and wellbeing

Proposed [GID-QS10117] Expected publication date: TBC

Quality standard Proposed

Hepatitis C

Proposed [GID-QS10126] Expected publication date: TBC

Quality standard Proposed

Water borne infections

Proposed [GID-QS10125] Expected publication date: TBC

Quality standard Proposed

Vulnerable populations: strategies for tackling inequalities

Proposed [GID-QS10124] Expected publication date: TBC

Quality standard Proposed

Prevention and non-surgical treatment of pelvic floor failure/incompetence/prolapse

Proposed [GID-QS10129] Expected publication date: TBC

Quality standard Proposed

Depression in adults (update)

Proposed [GID-QS10057] Expected publication date: TBC

Quality standard Proposed

Lung cancer (update)

In development [GID-QS10132] Expected publication date: 13 December 2019

Quality standard In development

Maternal health

In development [GID-QS10077] Expected publication date: TBC

Quality standard In development

Flu vaccination: increasing uptake

In development [GID-QS10071] Expected publication date: 09 January 2020

Quality standard In development

School-based interventions: physical and mental health and wellbeing promotion

In development [GID-QS10070] Expected publication date: TBC

Quality standard In development

Adrenal dysfunction

Proposed [GID-QS10038] Expected publication date: TBC

Quality standard Proposed

Acne

Proposed [GID-QS10036] Expected publication date: TBC

Quality standard Proposed

Abdominal aortic aneurysm

Proposed [GID-QS10035] Expected publication date: TBC

Quality standard Proposed

Intrapartum care: existing medical conditions or obstetric complications

In development [GID-QS10081] Expected publication date: 04 February 2020

Quality standard In development

Indoor air quality at home

In development [GID-QS10113] Expected publication date: 20 October 2020

Quality standard In development

Suspected neurological conditions

In development [GID-QS10082] Expected publication date: 03 July 2020

Quality standard In development

Abortion care

In development [GID-QS10084] Expected publication date: 18 August 2020

Quality standard In development

Cerebral palsy in adults

In development [GID-QS10080] Expected publication date: 23 January 2020

Quality standard In development

Specialist neonatal respiratory care for babies born preterm: quality standard consultation

We are listening to your views on this quality standard. Comments close 11 November 2019.

Quality standard In consultation

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID1504

In development [GID-TA10400] Expected publication date: 11 December 2019

Technology appraisal guidance In development

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)

NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published April 2019

Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)

NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive

Technology appraisal guidance Published February 2019

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from

Technology appraisal guidance Published March 2019

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the

Technology appraisal guidance Published March 2019

Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults

Technology appraisal guidance Published May 2019

Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)

NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence

Technology appraisal guidance Published December 2018

Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)

NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was

Technology appraisal guidance Published December 2018